Oral Therapies in Psoriasis Management: A Debate on Deucravacitinib vs Apremilast

Panelists discuss how oral psoriasis therapies enhance flexibility and patient-centered treatment options across varying disease severities.

Panelists discuss how deucravacitinib and apremilast act through distinct immune pathways that shape their efficacy, safety, and therapeutic roles.

Panelists discuss how clinical evidence shows deucravacitinib’s superior efficacy over apremilast while underscoring the need for individualized therapy selection.

Panelists discuss how clinical evidence shows deucravacitinib’s superior efficacy over apremilast while underscoring the need for individualized therapy selection.

Panelists discuss how deucravacitinib provides greater scalp and high-impact site clearance than apremilast, supporting more personalized psoriasis care.

Panelists discuss how both oral agents exhibit reassuring long-term safety and tolerability that support continued use in diverse psoriasis populations.

Panelists discuss how practical factors such as dosing, monitoring, and patient preference shape optimal use of oral psoriasis therapies.

Panelists discuss how the treatment landscape for psoriasis continues to evolve, with oral agents expected to play an expanding role alongside biologics. Ongoing innovation in TYK2 inhibition and PDE4 modulation may yield even more effective and tolerable options, reshaping patient expectations for convenience and control. Panelists discuss how integration of real-world data and head-to-head comparisons will clarify positioning of oral therapies across disease severities. Future directions include exploring combination strategies and earlier oral intervention to delay or reduce biologic use. Panelists discuss how continued advancement in oral therapy represents a broader shift toward personalized, accessible psoriasis care that empowers patients and supports sustained disease control.